<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 03-May-2017 [07:24:35] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.tapimmune.com/20170331" elementFormDefault="qualified" xmlns:tpiv="http://www.tapimmune.com/20170331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.tapimmune.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity" id="CondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>105 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&#39; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>107 - Disclosure - NATURE OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>108 - Disclosure - BASIS OF PRESENTATION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialCondition" id="LiquidityAndFinancialCondition">
        <link:definition>109 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>110 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholder" id="NetLossPerShareApplicableToCommonShareholder">
        <link:definition>111 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
        <link:definition>112 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements" id="WarrantLiabilityAndFairValueMeasurements">
        <link:definition>113 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/PromissoryNote" id="PromissoryNote">
        <link:definition>114 - Disclosure - PROMISSORY NOTE</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>115 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>116 - Disclosure - STOCK-BASED COMPENSATION</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SubsequentEvent" id="SubsequentEvent">
        <link:definition>117 - Disclosure - SUBSEQUENT EVENT</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>118 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholderTables" id="NetLossPerShareApplicableToCommonShareholderTables">
        <link:definition>119 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>120 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsTables" id="WarrantLiabilityAndFairValueMeasurementsTables">
        <link:definition>121 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail" id="LiquidityAndFinancialConditionAdditionalInformationDetail">
        <link:definition>122 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholderComputationOfIncomeLossPerShareDetail" id="NetLossPerShareApplicableToCommonShareholderComputationOfIncomeLossPerShareDetail">
        <link:definition>123 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholderPotentiallyDilutiveSecuritiesDetail" id="NetLossPerShareApplicableToCommonShareholderPotentiallyDilutiveSecuritiesDetail">
        <link:definition>124 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/AccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetail" id="AccountsPayableAndAccruedLiabilitiesAccountsPayableAndAccruedLiabilitiesDetail">
        <link:definition>125 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Accounts payable and accrued liabilities (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail" id="AccountsPayableAndAccruedLiabilitiesAdditionalInformationDetail">
        <link:definition>126 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/ResearchAgreementsAdditionalInformationDetail" id="ResearchAgreementsAdditionalInformationDetail">
        <link:definition>127 - Disclosure - RESEARCH AGREEMENTS - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail" id="WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail">
        <link:definition>128 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>129 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail" id="WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail">
        <link:definition>130 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/PromissoryNoteAdditionalInformationDetail" id="PromissoryNoteAdditionalInformationDetail">
        <link:definition>131 - Disclosure - PROMISSORY NOTE - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
        <link:definition>132 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.tapimmune.com/role/StockbasedCompensationAdditionalInformationDetail" id="StockbasedCompensationAdditionalInformationDetail">
        <link:definition>133 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="tpiv-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_DocumentAndEntityInformationAbstract" />

  <element name="ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="tpiv_ReclassificationOfAccruedLiabilityUponIssuanceOfCommonSharesRelatingToCompensation" />

  <element name="SharePurchaseWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SharePurchaseWarrantsMember" />

  <element name="CommonStockCapitalSharesReservedForFutureIssuanceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tpiv_CommonStockCapitalSharesReservedForFutureIssuanceTable" />

  <element name="ConsultingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ConsultingAgreementsMember" />

  <element name="LiquidityAndFinancialConditionTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_LiquidityAndFinancialConditionTextBlock" />

  <element name="DerivativesAndFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_DerivativesAndFairValueAbstract" />

  <element name="ValuationMethodology" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_ValuationMethodology" />

  <element name="FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" />

  <element name="MeasuredAtFairValue" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_MeasuredAtFairValue" />

  <element name="PromissoryNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PromissoryNotesAbstract" />

  <element name="PromissoryNoteTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PromissoryNoteTextBlock" />

  <element name="SupplementalScheduleOfNoncashActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_SupplementalScheduleOfNoncashActivitiesAbstract" />

  <element name="NotestofinancialstatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_NotestofinancialstatementsAbstract" />

  <element name="CommonStockWarrantsEquityTreatment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CommonStockWarrantsEquityTreatment" />

  <element name="CommonStockWarrantsLiabilityTreatment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CommonStockWarrantsLiabilityTreatment" />

  <element name="NetLossPerShareTableTextBlockTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_NetLossPerShareTableTextBlockTableTextBlock" />

  <element name="AccountsPayableAndAccruedLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tpiv_AccountsPayableAndAccruedLiabilitiesTable" />

  <element name="AccountsPayableAndAccruedLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_AccountsPayableAndAccruedLiabilitiesLineItems" />

  <element name="AccruedConsultingAgreementsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="tpiv_AccruedConsultingAgreementsCurrent" />

  <element name="AccruedTechnologyLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="tpiv_AccruedTechnologyLicenseFees" />

  <element name="AccruedInvestorRelationsFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="tpiv_AccruedInvestorRelationsFeesCurrent" />

  <element name="CommonStockCapitalSharesReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />

  <element name="PromissoryNotesDueInTwoThousandTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PromissoryNotesDueInTwoThousandTwelveMember" />

  <element name="PresidentAndChiefOperatingOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tpiv_PresidentAndChiefOperatingOfficerMember" />
</schema>

